和黄医药（HUTCHMED）已正式启动其正在进行的索凡替尼（surufatinib）与卡瑞利珠单抗（camrelizumab）联合疗法针对初治胰腺导管腺癌（PDAC）患者的III期临床试验阶段。
该研究旨在评估这一组合疗法在未曾接受过系统性治疗的胰腺导管腺癌患者中的疗效与安全性。胰腺导管腺癌作为一种恶性程度高、预后极差的消化道肿瘤，目前临床治疗选择有限，患者生存率普遍较低。
和黄医药此次推进至III期研究，标志着该联合疗法在前期临床试验中展现出潜在的应用前景。若III期试验结果积极，有望为胰腺导管腺癌患者提供新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.